Taiwanese journal of obstetrics & gynecology · 2026
Platinum sensitivity drives prognosis in endometriosis-associated ovarian carcinoma compared with high-grade serous ovarian carcinoma: Insights from a 10-year retrospective study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sung Yu-Wen, Chi Hsiang-Cheng, Li Tsai-Chung, Lin Wu-Chou, Hung Yao-Ching, Chang Wei-Chun, Yin-Yi Chang Cherry, Chang Yu-Wei, Lee Kam-Fai, Yeh Lian-Shung
Аннотация
OBJECTIVE: To compare clinical features, treatment responses, and survival outcomes between endometriosis-associated ovarian cancer (EAOC) and high-grade serous ovarian carcinoma (HGSOC), with a focus on platinum resistance.
MATERIALS AND METHODS: We conducted a 10-year retrospective study of 224 patients with epithelial ovarian cancer treated at a single tertiary medical center in Taiwan. Patients were classified as either EAOC (clear cell or endometrioid histology) or HGSOC. Clinical data, surgical outcomes, platinum sensitivity, and survival were analyzed.
RESULTS: EAOC patients were younger, more often diagnosed at early stage, and achieved higher rates of optimal cytoreduction compared to HGSOC. Overall survival (OS) and progression-free survival (PFS) were significantly better in the EAOC group. However, survival advantages diminished after stratification by stage and platinum sensitivity. Notably, no platinum-resistant EAOC patient survived beyond 5 years, whereas a subset of platinum-resistant HGSOC patients achieved long-term survival.
CONCLUSION: Although EAOC generally confers a favorable prognosis due to earlier diagnosis and better surgical outcomes, platinum resistance remains a key driver of poor survival. These findings highlight the importance of tailored treatment approaches and early identification of chemoresistance, especially in clear cell subtypes prevalent in Asian populations.
MATERIALS AND METHODS: We conducted a 10-year retrospective study of 224 patients with epithelial ovarian cancer treated at a single tertiary medical center in Taiwan. Patients were classified as either EAOC (clear cell or endometrioid histology) or HGSOC. Clinical data, surgical outcomes, platinum sensitivity, and survival were analyzed.
RESULTS: EAOC patients were younger, more often diagnosed at early stage, and achieved higher rates of optimal cytoreduction compared to HGSOC. Overall survival (OS) and progression-free survival (PFS) were significantly better in the EAOC group. However, survival advantages diminished after stratification by stage and platinum sensitivity. Notably, no platinum-resistant EAOC patient survived beyond 5 years, whereas a subset of platinum-resistant HGSOC patients achieved long-term survival.
CONCLUSION: Although EAOC generally confers a favorable prognosis due to earlier diagnosis and better surgical outcomes, platinum resistance remains a key driver of poor survival. These findings highlight the importance of tailored treatment approaches and early identification of chemoresistance, especially in clear cell subtypes prevalent in Asian populations.